Abstract
Over the last 10 years, promising data has emerged from both animal and human studies that both active immunization with amyloid-β (Aβ) as well as passive immunization with anti-Aβ antibodies offer promise as therapies for Alzheimers disease (AD). Data from animal models suggests that antibodies to Aβ through several mechanisms can decrease Aβ deposition, decrease Aβ -associated damage such as dystrophic neurite formation, and improve behavioral performance. Data from human studies suggests that active immunization can result in plaque clearance and that passive immunotherapy might result in slowing of cognitive decline. Despite this, a recent analysis from a phase I trial that involved active immunization with Aβ42, while not powered to determine efficacy, suggested no large effect of active immunization despite the fact that plaque clearance was very prominent in some subjects. An important issue to consider is when active or passive immunization targeting Aβ has the chance to be most effective. Clinico-pathological and biomarker studies have shown that in terms of the time course of AD, Aβ deposition probably begins about 10-15 years prior to symptom onset (preclinical AD) and that tau aggregation in tangles and in neurites does not begin to accelerate and build up in larger amounts in the neocortex until just prior to symptom onset. By the time the earliest clinical signs of AD emerge, Aβ deposition may be close to reaching its peak and tangle formation and neuronal cell loss is substantial though still not at its maximal extent. Since immunization targeting Aβ does not appear to have major effects on tangle pathology, for immunization to have the most chance for success, performing clinical trials in individuals who are cognitively only very mildly impaired or even in those with preclinical AD would likely offer a much better chance for success. Current work with AD biomarkers suggests that such individuals can now be identified and it seems likely that targeting this population with immunization strategies targeting Aβ would offer the best chance of success.
Keywords: Alzheimer's disease, immunization, biomarkers, amyloid-β, tau, imaging, antecedent biomarkers, plaques
CNS & Neurological Disorders - Drug Targets
Title: Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
Volume: 8 Issue: 2
Author(s): Rawan Tarawneh and David M. Holtzman
Affiliation:
Keywords: Alzheimer's disease, immunization, biomarkers, amyloid-β, tau, imaging, antecedent biomarkers, plaques
Abstract: Over the last 10 years, promising data has emerged from both animal and human studies that both active immunization with amyloid-β (Aβ) as well as passive immunization with anti-Aβ antibodies offer promise as therapies for Alzheimers disease (AD). Data from animal models suggests that antibodies to Aβ through several mechanisms can decrease Aβ deposition, decrease Aβ -associated damage such as dystrophic neurite formation, and improve behavioral performance. Data from human studies suggests that active immunization can result in plaque clearance and that passive immunotherapy might result in slowing of cognitive decline. Despite this, a recent analysis from a phase I trial that involved active immunization with Aβ42, while not powered to determine efficacy, suggested no large effect of active immunization despite the fact that plaque clearance was very prominent in some subjects. An important issue to consider is when active or passive immunization targeting Aβ has the chance to be most effective. Clinico-pathological and biomarker studies have shown that in terms of the time course of AD, Aβ deposition probably begins about 10-15 years prior to symptom onset (preclinical AD) and that tau aggregation in tangles and in neurites does not begin to accelerate and build up in larger amounts in the neocortex until just prior to symptom onset. By the time the earliest clinical signs of AD emerge, Aβ deposition may be close to reaching its peak and tangle formation and neuronal cell loss is substantial though still not at its maximal extent. Since immunization targeting Aβ does not appear to have major effects on tangle pathology, for immunization to have the most chance for success, performing clinical trials in individuals who are cognitively only very mildly impaired or even in those with preclinical AD would likely offer a much better chance for success. Current work with AD biomarkers suggests that such individuals can now be identified and it seems likely that targeting this population with immunization strategies targeting Aβ would offer the best chance of success.
Export Options
About this article
Cite this article as:
Tarawneh Rawan and Holtzman M. David, Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention, CNS & Neurological Disorders - Drug Targets 2009; 8 (2) . https://dx.doi.org/10.2174/187152709787847324
DOI https://dx.doi.org/10.2174/187152709787847324 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain
Current Drug Targets Complications of Otitis Media
Infectious Disorders - Drug Targets Human Immunodeficiency Virus-Associated Malignancies: A Therapeutic Update
Current HIV Research Clinical Utility of Soluble CD163 and its Diagnostic and Prognostic Value in a Variety of Neurological Disorders
Mini-Reviews in Medicinal Chemistry Self-microemulsifying Drug Delivery System for Problematic Molecules: An Update
Recent Patents on Nanotechnology The Role of Macrophage Migration Inhibitory Factor in Critical Illness
Mini-Reviews in Medicinal Chemistry Microsomal Prostaglandin E Synthase: A Key Enzyme in PGE2 Biosynthesis and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology Ligand-modified Biopolymeric Nanoparticles as Efficient Tools for Targeted Cancer Therapy
Current Pharmaceutical Design Nitrergic Response to Clostridium perfringens Infection in the Rat Brain Regions Effect of Red Light Irradiation
Central Nervous System Agents in Medicinal Chemistry The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents HIV-1 Latency and Eradication: Past, Present and Future
Current HIV Research Natural Product-Based Phenolic and Nonphenolic Antimicrobial Food Preservatives and 1,2,3,4-Tetrahydroxybenzene as a Highly Effective Representative: A Review of Patent Literature 2000-2005
Recent Patents on Anti-Infective Drug Discovery Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews Pharmacokinetics of Topical Ocular Drug Delivery: Potential Uses for the Treatment of Diseases of the Posterior Segment and Beyond
Current Drug Metabolism The Potential Dual Effects of Anesthetic Isoflurane on Aβ-Induced Apoptosis
Current Alzheimer Research Lymphocytic Choriomeningitis Virus Infection: Neglected Teratogenic Zoonosis
Current Women`s Health Reviews Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design Is Hospital Autopsy Auditing Suitable for Clinical Risk Manage ment? Actualities and Perspectives of Auditing in the Autopsy Room Following Italian Law 24/2017 on Patient Safety
Current Pharmaceutical Biotechnology Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy